论文部分内容阅读
近年来分子靶向药物已成为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)可供选择的临床治疗方案。表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变与小分子EGFR酪氨酸激酶抑制剂(epidermal growth factor re-ceptor-tyrosine kinase inhibitor,EGFR-TKI)的临床疗效有一定相关性。然而,有些EGFR基因突变患者对EGFR-TKI的治疗并不敏感或对该类药物产生耐药。文中就EGFR基因突变与NSCLC分子靶向治疗敏感性和耐药机制的研究进展进行综述。
In recent years, molecular targeted drugs have become an alternative clinical treatment for advanced non-small cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) gene mutation and the small molecule EGFR-TKI clinical efficacy have a certain correlation. However, some patients with EGFR mutations are not sensitive or resistant to EGFR-TKI therapy. This review summarizes the research progress of the sensitivity and mechanism of EGFR gene mutation and NSCLC molecular targeted therapy.